Article

Spectable lens offers 'high definition' vision

The wavefront-guided lenses are made of programmable material that can be customized to each eye's 'optical fingerprint.'

SoCal has been the launch market for the first integrated, non-surgical, truly customized vision correction system. In addition to iZon lenses, the Ophthonix solution for optimizing vision also includes the Z-View aberrometer, which provides a more precise, objective examination. Measuring more than 11,300 points across each pupil, the Z-View produces a digital wavefront prescription, which is then used to program the iZon lens proprietary material to change the refractive index on a point-for-point basis. The process is comparable to burning a CD.

"There are over 1,500 iZon lens wearers, with more than 80% of patients giving the lenses the highest marks for overall satisfaction," said Andreas Dreher, PhD, Ophthonix president and CEO.

Among its other features are:

The Z-View aberrometer contains a "smart" proprietary algorithm, known as algiZon, that identifies the best candidates for iZon wavefront-guided spectacle lenses.

Patient satisfaction rates have run so high primarily because iZon lenses provide 10-fold greater accuracy, what some have called "high-definition" vision. The iZon lenses significantly improve visual acuity, low-contrast visual acuity, and contrast sensitivity.

Large numbers of patients have reported significantly improved night vision. The claim was validated by a study conducted with 30 subjects in a controlled FDA-validated night-driving simulator. The results showed that the iZon lenses can improve a driver's ability to identify pedestrians by an average of 330 milliseconds compared with conventional lenses.

"That means a driver can see a pedestrian or situation at about 30 ft. sooner at 55 mph, which is comparable to about three car lengths or the distance across a typical intersection," explained Dr. Dreher. "That 3/10 of a second could be a lifesaver."

From optical dispensing and refractive surgery perspectives, Mihir Parikh, MD, is pleased with the products. Dr. Parikh has used the Ophthonix system in his La Jolla, CA-based practice since June 2005. Patients have reported that the iZon lenses provide corrected vision that is as good as standard glasses and, in many cases, better.

"That's why you can confidently sell the product," said Dr. Parikh. The public has been made aware of wavefront technology through advertising by refractive surgeons. So the high-end technology attracts and wins over new patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.